Prolyl oligopeptidase: A rising star on the stage of neuroinflammation research

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 3, 2011, Pages 340-348

  Penttinen, Anne ^a   Tenorio Laranga, Jofre ^a   Siikanen, Anssi ^b   Morawski, Markus ^b   Roßner, Steffen ^b   García Horsman, J Arturo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Autoimmune disease; Glial activation; Neurodegeneration; Neuroinflammation; Prolyl oligopeptidase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ARGININE; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CHEMOKINE RECEPTOR CCR2; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; GLUTAMYL AMINOPEPTIDASE; GLYCINE; HEMORPHIN 4; INTERLEUKIN 8 RECEPTOR; LEUCYLLEUCINE; MACROPHAGE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; PROLINE; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STROMELYSIN 3; SUBSTANCE P; THROMBOSPONDIN; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ALLERGY; AMNESIA; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CELL ACTIVATION; CELL DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; ENCEPHALITIS; GENE MUTATION; GLIA CELL; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 79951683718     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794653742     Document Type: Article

References (93)

1. Polgar, L. Prolyl oligopeptidases. Methods Enzymol., 1994, 244, 188-200.
2. García-Horsman, J.A.; Männistö, P.T.; Venäläinen, J.I. On the role of prolyl oligopeptidase in health and disease. Neuropeptides, 2007, 41(1), 1-24.
3. Männistö, P.T.; Venäläinen, J.; Jalkanen, A.; García-Horsman, J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect., 2007, 20(5), 293-305.
4. Hashimoto, Y.; Kakegawa, H.; Narita, Y.; Hachiya, Y.; Hayakawa, T.; Kos, J.; Turk, V.; Katunuma, N. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun., 2001, 283(2), 334-339.
5. Kakegawa, H.; Matano, Y.; Inubushi, T.; Katunuma, N. Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice. Biochem. Biophys. Res. Commun., 2004, 316(1), 78-84.
6. Gaggar, A.; Jackson, P.L.; Noerager, B.D.; O'Reilly, P.J.; McQuaid, D.B.; Rowe, S.M.; Clancy, J.P.; Blalock, J.E. A novel proteolytic cascade generates an extra cellular matrix derived chemo attractant in chronic neutrophilic inflammation. J. Immunol., 2008, 180(8), 5662-5669.
7. Tenorio-Laranga, J.; Coret-Ferrer, F.; Casanova-Estruch, B.; Burgal, M.; Garcia-Horsman, J.A. Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J. Neuroinflammation, 2010, 7, 23.
8. Gaggar, A.; Rowe, S.M.; Matthew, H.; Blalock, J.E. Proline glycineproline (PGP) and high mobility group box protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation. Open Respir. Med. J., 2010, 4, 32-38.
9. Lühder, F.; Lee, D.H.; Gold, R.; Stegbauer, J.; Linker, R.A. Small but powerful: short peptide hormones and their role in autoimmune inflammation. J. Neuroimmunol., 2009, 217(1-2), 1-7.
10. Taupin, P. Adult neurogenesis pharmacology in neurological diseases and disorders. Expert Rev. Neurother., 2008, 8(2), 311-320.
11. Hickey, W.F. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol., 1999, 11(2), 125-137.
12. Lossinsky, A.S.; Shivers, R.R. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Rev. Histol. Histopathol., 2004, 19(2), 535-564.
13. Das, S.; Basu, A. Inflammation: a new candidate in modulating adult neurogenesis. J. Neurosci. Res., 2008, 86(6), 1199-1208.
14. Welches, W.R.; Brosnihan, K.B.; Ferrario, C.M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci., 1993, 52(18), 1461-1480.
15. Fülöp, V.; Bocskei, Z.; Polgar, L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell, 1998, 94(2), 161-170.
16. Polgár, L. The prolyl oligopeptidase family. Cell. Mol. Life Sci., 2002, 59(2), 349-362.
17. Fruitier-Arnaudin, I.; Cohen, M.; Coitoux, C.; Piot, J.M. In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase. Peptides, 2003, 24(8), 1201-1206.
18. Brandt, I.; De Vriendt, K.; Devreese, B.; Van Beeumen, J.; Van Dongen, W.; Augustyns, K.; De Meester, I.; Scharpe, S.; Lambeir, A.M. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides, 2005, 26(12), 2536-2546.
19. Fruitier-Arnaudin, I.; Cohen, M.; Bordenave, S.; Sannier, F.; Piot, J.M. Comparative effects of angiotensin IV and two hemorphins on angiotensin-converting enzyme activity. Peptides, 2002, 23(8), 1465-1470.
20. Schulze-Topphoff, U.; Prat, A.; Prozorovski, T.; Siffrin, V.; Paterka, M.; Herz, J.; Bendix, I.; Ifergan, I.; Schadock, I.; Mori, M.A.; Van Horssen, J.; Schroter, F.; Smorodchenko, A.; Han, M.H.; Bader, M.; Steinman, L.; Aktas, O.; Zipp, F. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med., 2009, 15(7), 788-793.
21. Boettger, A.; Kertscher, U.; Steinmann, C.; Baeger, U.; Siems, W.E.; Heder, G. Degradation of bradykinin in semen of ram and boar. Biochem. Pharmacol., 1993, 45(10), 1983-1988.
22. Heder, G.; Bottger, A.; Siems, W.E.; Rottmann, M.; Kertscher, U. The enzymatic degradation of bradykinin in semen of various species. Andrologia, 1994, 26(5), 295-301.
23. Li, P.; Chappell, M.C.; Ferrario, C.M.; Brosnihan, K.B. Angiotensin (1-7) augments bradykinin induced vasodilation by competing with ace and releasing nitric oxide. Hypertension, 1997, 29(1 Pt 2), 394-400.
24. Lima, C.V.; Paula, R.D.; Resende, F.L.; Khosla, M.C.; Santos, R.A. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension, 1997, 30(3 Pt 2), 542-548.
25. Porsti, I.; Bara, A.T.; Busse, R.; Hecker, M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: Implications for a novel angiotensin receptor. Br. J. Pharmacol., 1994, 111(3), 652-654.
26. Paula, R.D.; Lima, C.V.; Khosla, M.C.; Santos, R.A. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension, 1995, 26(6 Pt 2), 1154-1159.
27. Abbas, A.; Gorelik, G.; Carbini, L.A.; Scicli, A.G. Angiotensin(1-7) induces bradykinin mediated hypotensive responses in anesthetized rats. Hypertension, 1997, 30(2 Pt 1), 217-221.
28. Koon, H.W.; Pothoulakis, C. Immunomodulatory properties of substance p: the gastrointestinal system as a model. Ann. NY Acad. Sci., 2006, 1088, 23-40.
29. Laurenzi, M.A.; Persson, M.A.; Dalsgaard, C.J.; Haegerstrand, A. The neuropeptide substance p stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand. J. Immunol., 1990, 31(4), 529-533.
30. Karagiannides, I.; Kokkotou, E.; Tansky, M.; Tchkonia, T.; Giorgadze, N.; O'Brien, M.; Leeman, S.E.; Kirkland, J.L.; Pothoulakis, C. Induction of colitis causes inflammatory responses in fat depots: evidence for substance p pathways in human mesenteric preadipocytes. Proc. Natl. Acad. Sci. USA, 2006, 103(13), 5207-5212.
31. Karagiannides, I.; Pothoulakis, C. Substance p, obesity, and gut inflammation. Curr. Opin. Endocrinol. Diabetes Obes., 2009, 16(1), 47-52.
32. Rosenkranz, M.A. Substance p at the nexus of mind and body in chronic inflammation and affective disorders. Psychol. Bull., 2007, 133(6), 1007-1037.
33. Michael-Titus, A.T.; Fernandes, K.; Setty, H.; Whelpton, R. In vivo metabolism and clearance of substance p and co-expressed tachykinins in rat striatum. Neuroscience, 2002, 110(2), 277-286.
34. Nolte, W.M; Tagore, D.M.; Lane, W.S.; Saghatelian, A. Peptidomics of prolyl endopeptidase in the central nervous system. Biochemistry, 2009, 48(50), 11971-11981.
35. Schulz, I.; Gerhartz, B.; Neubauer, A.; Holloschi, A.; Heiser, U.; Hafner, M.; Demuth, H.U. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur. J. Biochem., 2002, 269(23), 5813-5820.
36. Maes, M.; Monteleone, P.; Bencivenga, R.; Goossens, F.; Maj, M.; van West, D.; Bosmans, E.; Scharpe, S. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology, 2001, 26(1), 17-26.
37. Maes, M.; Lin, A.H.; Bonaccorso, S.; Goossens, F.; Van Gastel, A.; Pioli, R.; Delmeire, L.; Scharpe, S. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J. Affect. Disord., 1999, 53(1), 27-34.
38. Maes, M.; Goossens, F.; Scharpe, S.; Calabrese, J.; Desnyder, R.; Meltzer, H.Y. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res., 1995, 58(3), 217-225.
39. Shapiro, S.D.; Ingenito, E.P. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am. J. Respir. Cell Mol. Biol., 2005, 32(5), 367-372.
40. Sheppard, M.N.; Nicholson, A.G. The pathology of cystic fibrosis. Curr. Diagn. Pathol., 2002, 8(1), 50-59.
41. Weathington, N.M.; van Houwelingen, A.H.; Noerager, B.D.; Jackson, P.L.; Kraneveld, A.D.; Galin, F.S.; Folkerts, G.; Nijkamp, F.P.; Blalock, J.E. A novel peptide cxcr ligand derived from extracellular matrix degradation during airway inflammation. Nat. Med., 2006, 12(3), 317-323.
42. O'Reilly, P.J.; Hardison, M.T.; Jackson, P.L.; Xu, X.; Snelgrove, R.J.; Gaggar, A.; Galin, F.S.; Blalock, J.E. Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, pgp, from collagen. J. Neuroimmunol., 2009, 217(1-2), 51-54.
43. Downs, J.T.; Lane, C.L.; Nestor, N.B.; McLellan, T.J.; Kelly, M.A.; Karam, G.A.; Mezes, P.S.; Pelletier, J.P.; Otterness, I.G. Analysis of collagenase cleavage of type ii collagen using a neoepitope elisa. J. Immunol. Methods, 2001, 247(1-2), 25-34.
44. Gaggar, A.; Li, Y.; Weathington, N.; Winkler, M.; Kong, M.; Jackson, P.; Blalock, J.E.; Clancy, J.P. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293(1), L96-L104.
45. O'Reilly, P.; Jackson, P.L.; Noerager, B.; Parker, S.; Dransfield, M.; Gaggar, A.; Blalock, J.E., N-alpha-pgp and pgp, potential biomarkers and therapeutic targets for copd. Respir. Res., 2009, 10, 38.
46. Henson, P.M.; Vandivier, R.W. The matrix degrades, neutrophils invade. Nat. Med., 2006, 12(3), 280-281.
47. Hardison, M.T.; Galin, F.S.; Calderon, C.E.; Djekic, U.V.; Parker, S.B.; Wille, K.M.; Jackson, P.L.; Oster, R.A.; Young, K.R.; Blalock, J.E.; Gaggar, A. The presence of a matrix derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J. Immunol., 2009, 182(7), 4423-4431.
48. Kamori, M.; Hagihara, M.; Nagatsu, T.; Iwata, H.; Miura, T. Activities of dipeptidyl peptidase ii, dipeptidyl peptidase iv, prolyl endopeptidase, and collagenase like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem. Med. Metab. Biol., 1991, 45(2), 154-160.
49. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. N. Engl. J. Med., 2008, 358(9), 929-939.
50. Hagihara, M.; Ohhashi, M.; Nagatsu, T. Activities of dipeptidyl peptidase ii and dipeptidyl peptidase iv in mice with lupus erythematosus like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin. Chem., 1987, 33(8), 1463-1465.
51. Aoyagi, T.; Wada, T.; Daskalov, H.P.; Kojima, F.; Nagai, M.; Harada, S.; Fujiwara, M.; Makino, M.; Umezawa, H. Dissociation between serine proteinases and proline related enzymes in spleen of mrl mouse as a model of systemic lupus erythematodes. Biochem. Int., 1987, 14(3), 435-441.
52. Cavasin, M.A.; Rhaleb, N.E.; Yang, X.P.; Carretero, O.A. Prolyl oligopeptidase is involved in release of the antifibrotic peptide ac-sdkp. Hypertension, 2004, 43(5), 1140-1145.
53. Lenfant, M.; Grillon, C.; Rieger, K.J.; Sotty, D.; Wdzieczak-Bakala, J. Formation of acetyl-ser-asp-lys-pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4. Ann. NY Acad. Sci., 1991, 628, 115-125.
54. Sharma, U.; Rhaleb, N.E.; Pokharel, S.; Harding, P.; Rasoul, S.; Peng, H.; Carretero, O.A. Novel anti-inflammatory mechanisms of n-acetylserasplyspro in hypertension-induced target organ damage. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(3), H1226-H1232.
55. Cavasin, M.A.; Liao, T.D.; Yang, X.P.; Yang, J.J.; Carretero, O.A. Decreased endogenous levels of acsdkp promote organ fibrosis. Hypertension, 2007, 50(1), 130-136.
56. Yang, F.; Yang, X.P.; Liu, Y.H.; Xu, J.; Cingolani, O.; Rhaleb, N.E.; Carretero, O.A. Acsdkp reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension, 2004, 43(2), 229-236.
57. Rasoul, S.; Carretero, O.A.; Peng, H.; Cavasin, M.A.; Zhuo, J.; Sanchez-Mendoza, A.; Brigstock, D.R.; Rhaleb, N.E. Antifibrotic effect of acsdkp and angiotensin converting enzyme inhibition in hypertension. J. Hypertens., 2004, 22(3), 593-603.
58. + t cells in multiple sclerosis: A new target for therapy? Brain, 2005, 128(Pt 8), 1747-1763.
59. Bar-Or, A.; Oliveira, E.M.; Anderson, D.E.; Hafler, D.A. Molecular pathogenesis of multiple sclerosis. J. Neuroimmunol., 1999, 100(1-2), 252-259.
60. Steinman, L. Multiple sclerosis: A two-stage disease. Nat. Immunol., 2001, 2(9), 762-764.
61. Sawai, S.; Umemura, H.; Mori, M.; Satoh, M.; Hayakawa, S.; Kodera, Y.; Tomonaga, T.; Kuwabara, S.; Nomura, F. Serum levels of complement c4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis. J. Neuroimmunol., 2010, 218(1-2), 112-115.
62. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol., 2007, 61(4), 288-299.
63. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol., 2007, 61(6), 504-513.
64. Sadovnick, A.D.; Ebers, G.C.; Dyment, D.A.; Risch, N.J. Evidence for genetic basis of multiple sclerosis.The canadian collaborative study group. Lancet, 1996, 347(9017), 1728-1730.
65. Schmidt, S.; Hertfelder, H.J.; von Spiegel, T.; Hering, R.; Harzheim, M.; Lassmann, H.; Deckert-Schluter, M.; Schlegel, U. Lethal capillary leak syndrome after a single administration of interferon beta-1b. Neurology, 1999, 53(1), 220-222.
66. McGeer, E.G.; McGeer, P.L. Inflammatory processes in alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(5), 741-749.
67. Manicone, A.M.; McGuire, J.K. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol., 2008, 19(1), 34-41.
68. Klegeris, A.; Li, J.; Bammler, T.K.; Jin, J.; Zhu, D.; Kashima, D.T.; Pan, S.; Hashioka, S.; Maguire, J.; McGeer, P.L.; Zhang, J. Prolyl endopeptidase is revealed following silac analysis to be a novel mediator of human microglial and thp-1 cell neurotoxicity. Glia, 2008, 56(6), 675-685.
69. Correale, J.; Bassani Molinas Mde, L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of ms. J. Neuroimmunol., 2003, 140(1-2), 198-209.
70. Hartung, H.P.; Kieseier, B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol., 2000, 107(2), 140-147.
71. Ortiz, G.G.; Macias-Islas, M.A.; Pacheco-Moises, F.P.; Cruz-Ramos, J.A.; Sustersik, S.; Barba, E.A.; Aguayo, A. Oxidative stress is increased in serum from mexican patients with relapsingremitting multiple sclerosis. Dis. Markers, 2009, 26(1), 35-39.
72. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol., 2004, 251(3), 261-268.
73. Naidoo, R.; Knapp, M.L. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin. Chem., 1992, 38(12), 2449-2454.
74. Han, M.H.; Hwang, S.I.; Roy, D.B.; Lundgren, D.H.; Price, J.V.; Ousman, S.S.; Fernald, G.H.; Gerlitz, B.; Robinson, W.H.; Baranzini, S.E.; Grinnell, B.W.; Raine, C.S.; Sobel, R.A.; Han, D.K.; Steinman, L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature, 2008, 451(7182), 1076-1081.
75. Skidgel, R.A. Bradykinin-degrading enzymes: Structure, function, distribution, and potential roles in cardiovascular pharmacology. J. Cardiovasc. Pharmacol., 1992, 20(Suppl 9), S4-S9.
76. Odaka, C.; Mizuochi, T.; Shirasawa, T.; Morain, P.; Checler, F. Murine t cells expressing high activity of prolyl endopeptidase are susceptible to activation-induced cell death. FEBS Lett., 2002, 512(1-3), 163-167.
77. Klegeris, A.; McGeer, P.L. Chymotrypsin like proteases contribute to human monocytic thp-1 cell as well as human microglial neurotoxicity. Glia, 2005, 51(1), 56-64.
78. Zhao, F.L.; Hu, J.H.; Zhu, X.Z. Monocyte mediated rotenone neurotoxicity towards human neuroblastoma sh-sy5y: Role of mitogenactivated protein kinases. Biol. Pharm. Bull., 2006, 29(7), 1372-1377.
79. Toide, K.; Iwamoto, Y.; Fujiwara, T.; Abe, H.J.; Tp-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J. Pharmacol. Exp. Ther., 1995, 274(3), 1370-1378.
80. Rossner, S.; Schliebs, R.; Perez-Polo, J.R.; Wiley, R.G.; Bigl, V. Differential changes in cholinergic markers from selected brain regions after specific immunolesion of the rat cholinergic basal forebrain system. J. Neurosci. Res., 1995, 40(1), 31-43.
81. Rossner, S.; Hartig, W.; Schliebs, R.; Bruckner, G.; Brauer, K.; Perez-Polo, J.R.; Wiley, R.G.; Bigl, V. 192igg-saporin immunotoxin-induced loss of cholinergic cells differentially activates microglia in rat basal forebrain nuclei. J. Neurosci. Res., 1995, 41(3), 335-346.
82. Rossner, S.; Schulz, I.; Zeitschel, U.; Schliebs, R.; Bigl, V.; Demuth, H.U. Brain prolyl endopeptidase expression in aging, app transgenic mice and alzheimer's disease. Neurochem. Res., 2005, 30(6-7), 695-702.
83. Myöhänen, T.T.; García-Horsman, J.A.; Tenorio-Laranga, J.; Männistö, P.T. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mrna, protein levels, and enzymatic activity. J. Histochem. Cytochem., 2009, 57(9), 831-848.
84. Brandt, I.; Scharpe, S.; Lambeir, A.M. Suggested functions for prolyl oligopeptidase: a puzzling paradox. Clin. Chim. Acta, 2007, 377(1-2), 50-61.
85. Harwood, A.J. Lithium and bipolar mood disorder: the inositoldepletion hypothesis revisited. Mol. Psychiatry, 2005, 10(1), 117-126.
86. Breen, G.; Harwood, A.J.; Gregory, K.; Sinclair, M.; Collier, D.; St Clair, D.; Williams, R.S. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord., 2004, 6(2), 156-161.
87. Williams, R.S.; Cheng, L.; Mudge, A.W.; Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature, 2002, 417(6886), 292-295.
88. Schulz, I.; Zeitschel, U.; Rudolph, T.; Ruiz-Carrillo, D.; Rahfeld, J.U.; Gerhartz, B.; Bigl, V.; Demuth, H.U.; Rossner, S. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem., 2005, 94(4), 970-979.
89. Baird, J.L.; Raper, J.A. A serine proteinase involved in contact mediated repulsion of retinal growth cones by drg neurites. J. Neurosci., 1995, 15(10), 6605-6618.
90. Di Daniel, E.; Glover, C.P.; Grot, E.; Chan, M.K.; Sanderson, T.H.; White, J.H.; Ellis, C.L.; Gallagher, K.T.; Uney, J.; Thomas, J.; Maycox, P.R.; Mudge, A.W. Prolyl oligopeptidase binds to gap-43 and functions without its peptidase activity. Mol. Cell Neurosci., 2009, 41(3), 373-382.
91. King, J.; Keim, M.; Teo, R.; Weening, K.E.; Kapur, M.; McQuillan, K.; Ryves, J.; Rogers, B.; Dalton, E.; Williams, R.S.; Harwood, A.J. Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes. PLoS One, 2010, 5(6), e11151.
92. Bazzichi, L.; Ciompi, M.L.; Betti, L.; Rossi, A.; Melchiorre, D.; Fiorini, M.; Giannaccini, G.; Lucacchini, A. Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. Clin. Exp. Rheumatol., 2002, 20(6), 761-766.
93. Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140(6), 918-934.